French Drug Industry Group Kicked Off Key Gov't Committee
This article was originally published in The Pink Sheet Daily
France will eliminate industry seat on the nation's HTA transparency panel, in apparent continuing Mediator fall-out.
You may also be interested in...
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.
The scandal surrounding the withdrawal of Servier’s diabetes drug Mediator (benfluorex) continues to rock the French medical establishment, but it also has drawn attention to the issue of regulators' transparency more broadly – including at the European Medicines Agency.
Jean Marimbert's resignation over the Mediator affair also highlights larger issues of regulatory transparency and better pharmacovigilance.